Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5084402
Max Phase: Preclinical
Molecular Formula: C17H13Cl2N3OS
Molecular Weight: 378.28
Molecule Type: Unknown
Associated Items:
ID: ALA5084402
Max Phase: Preclinical
Molecular Formula: C17H13Cl2N3OS
Molecular Weight: 378.28
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(CSc1nccn1-c1cccc(Cl)c1)Nc1ccc(Cl)cc1
Standard InChI: InChI=1S/C17H13Cl2N3OS/c18-12-4-6-14(7-5-12)21-16(23)11-24-17-20-8-9-22(17)15-3-1-2-13(19)10-15/h1-10H,11H2,(H,21,23)
Standard InChI Key: PFPWNZHVLCEPGS-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 378.28 | Molecular Weight (Monoisotopic): 377.0156 | AlogP: 4.91 | #Rotatable Bonds: 5 |
Polar Surface Area: 46.92 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.60 | CX Basic pKa: 4.47 | CX LogP: 4.86 | CX LogD: 4.86 |
Aromatic Rings: 3 | Heavy Atoms: 24 | QED Weighted: 0.64 | Np Likeness Score: -2.77 |
1. (2021) Slc26a3 inhibitors and use thereof, |
Source(1):